NCK adaptor protein 1Genealiases: NCK · NCKalpha · nck-1
Q-omics provides the consensus-scored NCK1 profile across patient tissues and cancer cell-line models. NCK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCK1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NCK1 protein abundance shows 24,224 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where NCK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCK1 survival associations across molecular data types. NCK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCK1 RNA expression–survival associations across cancer types. High NCK1 expression shows unfavorable associations in KICH, PAAD, UVM and KIRP, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCK1 RNA expression.
This table summarizes NCK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCK1 shows lower tumor expression in THCA, COAD and BRCA and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher NCK1 RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with NCK1 in patient tissues and cancer cell lines. In patient samples, NCK1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
